Ingrid Jakobsen Falk (Ingrid Jakobsen)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 6

Top Topics

Ejection Fraction

Gene Expression

Top Venues

Basic & clinical pharmacology & toxicology

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Ingrid Jakobsen Falk, Max Sundkvist, Niclas Björn, Henrik Green, Kourosh Lotfi
Early changes in gene expression profiles in AML patients during induction chemotherapy. BMC genomics 23 (1) (2022)
Niclas Björn, Ingrid Jakobsen Falk, Chihiro Udagawa, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, Hitoshi Zembutsu, Henrik Green
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes. Basic & clinical pharmacology & toxicology 130 (4) (2022)
Anna Åstrand, Svante Vikingsson, Ingrid Jakobsen Falk, Niclas Björn, Robert Kronstrand, Henrik Green
Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure. Drug testing and analysis 13 (1) (2020)
Niclas Björn, Ingrid Jakobsen Falk, Kourosh Lotfi, Henrik Green
Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin. Genes 11 (5) (2020)
Niclas Björn, Ingrid Jakobsen Falk, Ignace Vergote, Henrik Green
ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients. Basic & clinical pharmacology & toxicology 123 (3) (2018)
Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen, Astrid Gruber, Evren Alici, Birgitta Lauri, Cecilie Blimark, Ulf-Henrik Mellqvist, Agneta Swedin, Karin Forsberg, Conny Carlsson, Mats Hardling, Lucia Ahlberg, Kourosh Lotfi, Hareth Nahi
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer chemotherapy and pharmacology 81 (1) (2017)